Haemonetics (HAE) Equity Average (2010 - 2026)

Haemonetics has reported Equity Average for 17 years, with the latest figure at $853.9 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 1.15% year-over-year to $853.9 million; the trailing twelve-month figure through Mar 2026 stood at $853.9 million (down 1.15% YoY), and the FY2026 full-year result was $808.6 million, down 9.19% from the prior year.
• Equity Average for Q1 2026 stood at $853.9 million, down from $880.3 million in the prior quarter.
• The five-year high for Equity Average was $951.6 million in Q1 2024, with the low at $714.7 million in Q1 2022.
• Average Equity Average over 5 years is $841.0 million, with a median of $858.9 million recorded in 2025.
• Year-over-year, Equity Average advanced 22.06% in 2023 and decreased 9.23% in 2025.
• Tracing HAE's Equity Average over 5 years: stood at $752.5 million in 2022, then gained by 22.06% to $918.5 million in 2023, then slipped by 2.79% to $892.9 million in 2024, then slipped by 1.4% to $880.3 million in 2025, then declined by 3.0% to $853.9 million in 2026.
• The last three Equity Average figures came in at $853.9 million (Q1 2026), $880.3 million (Q4 2025), and $865.7 million (Q3 2025), per Business Quant data.

Peer Comparison